kX-50 50 mg (Tablet)

Unit Price: ৳ 30.09 (5's pack: ৳ 150.45)

Medicine Details

Selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5)
Requires sexual stimulation to be effective
Results in smooth muscle relaxation and increased blood flow to the penile tissues

Mechanism of Action: Involves releasing nitric oxide in the corpus cavernosum during sexual stimulation, activation of guanylate cyclase, and increased levels of cGMP
Pharmacokinetics and Metabolism: Rapid absorption after oral administration, hepatic metabolism by cytochrome P450 3A4, and conversion to active metabolite with similar properties
Absorption and Distribution: Rapidly absorbed, maximum plasma concentrations reached within 30 to 120 minutes
Metabolism and Excretion: Cleared by hepatic microsomal isoenzymes, excreted as metabolites predominantly in feces and to a lesser extent in urine
Pharmacokinetics in Special Populations: Elderly volunteers (65 years or over) had reduced clearance, resulting in higher plasma AUC values

Erectile Dysfunction:
- Recommended dose is 50 mg taken approximately 1 hour before sexual activity, with possibility of adjustment to 100 mg or decrease to 25 mg based on effectiveness and toleration
- Max recommended dosing frequency is once per day
- Factors associated with increased plasma levels include age >65, hepatic impairment, severe renal impairment, and concomitant use of potent cytochrome P450 3A4 inhibitors
Pulmonary Arterial Hypertension:
- Recommended dose is 20 mg three times a day, taken approximately 4-6 hours apart, with or without food

Metabolism: Principally mediated by cytochrome P450 (CYP) isoforms 3A4 and 2C9
Inhibitors:
- Cimetidine, erythromycin, saquinavir, ketoconazole, itraconazole, ritonavir, and protease inhibitors can increase kX-50 concentrations
- Strong CYP3A4 inhibitors expected to have greater effects

Various systemic and specific adverse effects related to different body systems
Serious cardiovascular, cerebrovascular, and vascular events reported post-marketing
Potential for prolonged erection, priapism, hematuria, and visual disturbances

Pregnancy category B with no adequate and well-controlled studies in pregnant women
Not indicated for use by women, animal studies show no evidence of teratogenicity or embryotoxicity

General:
- Evaluation of erectile dysfunction should include determination of potential underlying causes and appropriate treatment following complete medical assessment
Vasodilatory Effects:
- Caution advised when co-administered with alpha-blockers as both are vasodilators with blood-pressure-lowering effects
- Potential for additive effect on blood pressure
- Safety of combined use affected by various variables including intravascular volume depletion
Cardiac Risk:
- Potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease
- Systemic vasodilatory properties should be carefully considered in patients with underlying cardiovascular disease
Sensitive Patient Groups:
- Patients with specific underlying conditions such as left ventricular outflow obstruction, severely impaired autonomic control of blood pressure, and certain cardiovascular disorders
Special Groups:
- Lack of controlled clinical data on safety or efficacy in specific groups including those with recent myocardial infarction, resting hypotension or hypertension, certain heart conditions, retinal disorders, and certain anemias